Most neurodegenerative diseases are linked to aberrant accumulation of aggregation-prone proteins. Among them, Huntington's disease (HD) is caused by an expanded polyglutamine repeat stretch in the N terminus of the mutant huntingtin protein (mHTT), which gets cleaved and aggregates in the brain. Recently established human induced pluripotent stem cell-derived HD neurons exhibit some diseaserelevant phenotypes and provide tools for HD research. However, they have limitations such as genetic heterogeneity and an absence of mHTT aggregates and lack a robust neurodegeneration phenotype. In addition, the relationship between the phenotype and mHTT levels has not been elucidated. Herein, we present a human embryonic stem cell (hESC)-derived HD neuronal model expressing HTTexon1 fragments, which addresses the deficiencies enumerated above. The wild-type and HD lines are derived from an isogenic background and exhibit insoluble mHTT aggregates and neurodegeneration. We also demonstrate a quantitative relationship between neurodegeneration and soluble monomeric (but not oligomeric or aggregated) mHTT levels. Reduction of ϳ10% of mHTT is sufficient to prevent toxicity, whereas ϳ90% reduction of wild-type HTT is safe and well-tolerated in these cells. A known HD toxicity modifier (Rhes) showed expected rescue of neurodegeneration. Therefore, the hESC-derived neuronal models complement existing induced pluripotent stem cell-derived neuronal models and provide valuable tools for HD research.-Lu, B., Palacino, J. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J. 27, 000 -000 (2013). www.fasebj.org
Abbreviations: DAPI, 4=,6-diamidino-2-phenylindole; HD, Huntington's disease; hESC, human embryonic stem cell; hiPSC, human induced pluripotent stem cell; HTT, huntingtin; iPSC, induced pluripotent stem cell; mHTT, mutant huntingtin; PBS, phosphate-buffered saline; polyQ, polyglutamine repeat; qPCR, quantitative polymerase chain reaction; TR-FRET, time-resolved fluorescence resonance energy transfer; wtHTT, wild-type huntingtin are limitations of the induced pluripotent stem cell (iPSC) technology, which may be compensated for by use of other complementary human neuronal models. First, comparison of phenotypes from iPSC-derived neurons is complicated by the fact that wild-type and HD lines are derived from different donors, so that genetic heterogeneity between samples is unavoidable. Second, the hiPSCderived HD neurons do not exhibit any detectable insoluble aggregates and thus cannot be used to study the pathological roles of aggregates, which are observed in human brains (8) . Consistent with the published results, we did not detect any mHTT aggregates in hiPSC-derived neurons that we have generated (Supplemental Fig. S1 ). Third, the most disease-relevant phenotype, neurodegeneration, is very subtle in the HD hiPSC-derived neurons and may not be robust enough for more complex applications, such as high-throughput screening (7) . Finally, the resource-and time-consuming process of making hiPSC-derived neuronal lines makes it challenging for their application in large-scale screening studies, which would be required for development of HD therapeutics.
Here we report on the generation of HD models from human embryonic stem cell (hESC)-derived neurons by stable transfection of cDNA encoding the HTTexon1 fragment containing a variety of polyQ lengths (Q23, wild-type; Q73 and Q145, HD). The HD and wild-type neurons are expressed on the same genetic background (H9) and exhibit polyQ-dependent aggregates. The neurons could be expanded to billions in number in a relatively short amount of time for screening purposes, and we have demonstrated that they are viable after freeze and thaw cycles. We have observed much more robust and severe neurodegeneration phenotypes in HD lines (Q73 and Q145), using assays that are compatible with highthroughput screening. Furthermore, we used this system to determine whether a therapeutic strategy aimed to lower HTT levels is beneficial in this cellular system. Notably, we established a quantitative relationship between rescue of neurodegeneration and the reduction of soluble monomeric mHTT levels. We further confirmed that lowering HTT, as well as a previously reported regulator of mHTT toxicity (Rhes), can rescue the neurodegeneration phenotype and demonstrate that reduction of ϳ90% wild-type huntingtin (wtHTT) protein was welltolerated in these neurons. Therefore, these models are suitable for further studies of the mechanism of mHTT toxicity and high-throughput screening targeting either mHTT levels or toxicity.
MATERIALS AND METHODS
hESC-derived stable neuronal cell line generation and culture conditions hESC line H9 (9) was used for the generation of neurons. hESCs were maintained in feeder-free conditions on growth factor-reduced Matrigel (BD Biosciences, San Jose, CA, USA) in mTeSR1 medium (Stem Cell Technologies, Vancouver, BC, Canada). For expansion, hESCs were enzymatically passaged with 1 mg/ml dispase treatment, and H9 cultures stably expressing HTTexon1 with 23, 73, or 145 glutamine repeats under the CAG promoter were generated using the ePiggyBac system. In brief, before dissociation and nucleofection, hESC cultures were treated for 1 h with 10 M ROCK inhibitor Y-27632. hESCs were then dissociated in 0.25% (w/v) trypsin-EDTA at 37°C for 5 min, washed in mTeSR1 with ROCK inhibitor, and resuspended in nucleofection solution V (Lonza AG, Cologne, Germany). Nucleofections were then performed with program setting B-016 to deliver a helper plasmid expressing the ePiggyBac transposase, a transposon containing a puromycin selection cassette, and a transcription unit expressing HTTexon1 with 23, 73, or 145 glutamine repeats under the CAG promoter. hESCs were then plated in mTeSR1 medium supplemented with 10 M ROCK inhibitor at densities of 2 ϫ 10 5 cells/6-cm dish. Culture medium was changed to mTeSR1 lacking ROCK inhibitor 20 -24 h after nucleofection, colonies were allowed to form for 7 d, and puromycin was subsequently added to select for transfected colonies. The transgenesis efficiency of the ePiggyBac construct allowed for the generation of several hundred puromycin-resistant colonies per 6-cm dish. These colonies were pooled and processed for neuronal differentiation.
hESC cultures were differentiated into neurons by dual inhibition of SMAD signaling, sorted by magnetic-activated cell sorting for surface expression of NCAM, and then maintained in Matrigel (BD Biosciences) in mTeSR1 medium (Stem Cell Technologies) with sustained SMAD inhibition (10). The wild-type, Q23, Q73, and Q145 lines were differentiated simultaneously for ϳ2 mo under these culture conditions, referred to as protective culture conditions. The majority of the cells expressed the neuronal marker Tuj1 (ϳ95%), were able to generate action potentials (ϳ73%), and exhibited prototypical neuronal morphology, including compact cell bodies, prominent nuclei, clear axons, and dendrites (see Fig. 1) . The neurons were then frozen and thawed or used directly for further experiments. All cell lines were maintained in a 37°C incubator with 5% CO 2 .
For detection of neurodegeneration, cells were cultured in protective culture conditions for 4 -6 d and then were enzymatically lifted by Accutase (Life Technologies, Carlsbad, CA, USA), collected by spinning at 1000 rpm for 4 min, and resuspended into the basal neuronal culture medium: Neurobasal medium (Life Technologies) supplemented with B27, 10 ng/ml human neurotrophin-3 (R&D Systems, Minneapolis, MN, USA), and 10 ng/ml human brain-derived neurotrophic factor (R&D Systems). The cells were then plated onto poly-d-lysine-coated 96-well plates (referred to as basal culture conditions) and phase-contrast or Live/Dead (L-3224; Life Technologies) imaging was performed on commercially available imaging systems (IncuCyte, Essen BioScience, Ann Arbor, MI, USA; or InCell, GE Healthcare Life Sciences, Chalfont St. Giles, UK, respectively). Confluence was calculated by the IncuCyte system based on the phasecontrast images from 4 independent fields for each well. For the nuclei counting assays, cells were incubated with Vybrant dye (V35004; Life Technologies) at 37°C for 30 min before detection of green fluorescent nuclei by the IncuCyte system. The sizes of representative fields for IncuCyte and Live/Dead imaging are both 0.4 ϫ 0.4 mm.
For most of the immunofluorescence and time-resolved fluorescence resonance energy transfer (TR-FRET) experiments (see below), the cells were kept under protective culture conditions to minimize cell death that may interfere with these measurements. For the TR-FRET experiments of the wild-type nontransfected neurons (see Fig. 5A ), the wild-type cells were cultured under basal culture conditions because they survive well under these conditions.
Immunofluorescence and confocal microscopy
For immunofluorescence, the cells were plated onto Matrigelcoated coverslips, incubated for 4 d (nontransfected or siRNA transfections), and fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS). Tuj1 antibody (Covance, Princeton, NJ, USA) was used as a neuronal marker, and HTT antibody EM48 (MAB5374; Millipore, Billerica, MA, USA) was used for the detection of HTT macroaggregates as described previously (8) . Map2 (SMI-52R; Covance) and Synapsin (106001; Synaptic Systems, Goettingen, Germany) were also detected as markers for more mature neurons. 4=,6-Diamidino-2-phenylindole (DAPI) was used for staining nuclei. The images were taken on a Zeiss LSM 510 META confocal microscope (Carl Zeiss, Thornwood, NY, USA) using a ϫ40 water-immersed objective lens (numerical aperture 1.30) by stacking the images taken by the Z-stack method (21 stacks with 1.1-m intervals). Quantification of total aggregate size and number of neurons with aggregates was performed in ImageJ (U.S. National Institutes of Health, Bethesda, MD, USA) by measuring the total area of EM48 signal above background divided by the total number of number of neurons in the field by counting.
Electrophysiology
For electrophysiology recordings, the pipette solution contained 135 mM potassium aspartate, 5 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , 4 mM CaCl 2 , 10 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP, 0.3 mM Tris-GTP, and 14 mM phosphocreatine (diTris; pH 7.4 with KOH, ϳ295 osmol/ml), and the bath solution contained 150 mM NaCl, 3.5 mM KCl, 1 mM MgCl 2 , 10 mM HEPES, 20 mM glucose, and 1.2 mM CaCl 2 (pH 7.4 with NaOH, ϳ320 osmol/ml). Liquid junction potentials (estimated using Clampex software; Axon, Union City, CA, USA) were corrected offline. Both voltage and current clamp recordings were performed using an Axopatch-200B amplifier controlled with MultiClamp software (Axon) and digitized at 10 kHz with a Digidata 1440 digitizer (Axon).
TR-FRET assay and Western blots
The TR-FRET assays were performed as described previously (11) . In brief, cells were lysed in buffer (1ϫ PBS ϩ 0.4% Triton X-100 ϩ 1ϫ Complete Mini Protease Inhibitor; Roche Applied Science, Indianapolis, IN, USA) on ice for 30 min and then were spun at 14,000 rpm and 4°C for 10 min. The supernatants were then taken for TR-FRET measurement. Different FRET antibody pairs were used for different experiments (11, 12) : terbium (Tb)-labeled HTT N-terminal antibody 2B7 paired with D2-labeled polyQ antibody MW1 (2B7/MW1) was used to measure soluble monomeric mHTT levels; Tb-labeled 4C9 (targeting the proline-rich domain in HTTexon1) paired with D2-labeled 4C9 (4C9/4C9) was used to measure Triton X-100-soluble, low-molecular-weight, oligomeric mHTT; 2B7-Tb paired with 4C9-D2 (2B7/4C9) was used to detect HTTexon1 fragments containing both long and short polyQ nonpreferentially; and 2B7-Tb paired with 2166-D2 (MAB2166; Millipore) was used for detection of wild-type full-length HTT. Note that the insoluble macroaggregates are largely excluded by spinning; therefore, 4C9/4C9 mainly detects the soluble oligomers of mHTT. The antibodies were added in the TR-FRET buffer (50 mM NaH 2 PO 4 , 400 mM NaF, 0.1% bovine serum albumin, and 0.05% Tween-20ϩantibody mix). The total protein concentration of each sample was measured by a BCA kit (23225; Pierce, Rockford, IL, USA) to ensure equal loading (100 ng for 2B7/MW1 and 2B7/4C9 TR-FRET and 1 g for 4C9/4C9 TR-FRET), and controls with serial dilutions were performed to ensure that the measurement was within the linear range.
For Western blots, the cells were lysed as described above, and the lysates were loaded onto 4 -12% Bis-Tris gel for Western blot analysis. Antibodies used for Western blot were Rhes (NBP2-03331; Novus Biologicals, Littleton, CO, USA) and anti-␤-actin (Ac-15, ab6276; Abcam, Cambridge, MA, USA).
siRNA transfection in hESC-derived neurons
siRNAs, at the concentrations indicated, were introduced by reverse transfection using RNAiMAX (Life Technologies) according to the manufacturer's protocol. For both transfected and nontransfected neurons, the cells were plated at 10,000 neurons/well in 96-well plates and proportionally increased for larger culture surfaces when needed. Note that relatively high siRNA concentrations (125 nM) are needed to achieve efficient knockdown, which is sustained over many days even after culture medium change in these cells (see Fig.  5A , right panel).
The target sequences of the siRNAs are as follows: HTTexon1 siRNA (13): ex1_si, GGCCTTCGAGTCCCTCAAGTCC; and HTT full-length siRNAs: HTT3, CAGGTTTATGAACTGAC-GTTA and Hdh5, ACCGTGTGAATCATTGTCTAA. The nontargeting scrambled control (Neg_si) and the Rhes siRNA are On-Targetplus siRNA SmartPools (Dharmacon RNA Technologies, Lafayette, CO, USA). Rhes knockdown was validated by quantitative polymerase chain reaction (qPCR) and Western blots (see Fig. 4C ).
RESULTS

Neurodegeneration phenotypes in mHTTexon1 stably transfected hESC-derived neurons
To generate a cellular model that recapitulates some HD phenotypes, we engineered hESCs expressing wtHTT and mHTT. HTTexon1 fragments were introduced into hESC cultures in the ePiggyBac transposase system to catalyze stable integration of the plasmids into the genome. After selection of expressing clones, these hESCs were subsequently differentiated into neurons. These neurons express the classic mature neuronal markers Tuj1, Map2, and Synapsin; exhibit prototypical neuronal morphology; and are able to generate action potentials (Fig. 1 ). After HTTexon1 with long polyQ (Q73 or Q145) but not short polyQ (Q23) was expressed from a stable integrated gene construct for several months, the neurons showed HTT macroaggregates as detected by immunostaining with the antibody EM48 (ref. 8 and Fig. 1A) . The expression of different species of HTTexon1 proteins was then determined by TR-FRET assays (Fig. 1D) . The 2B7/4C9 TR-FRET assay uses antibodies targeting polyQ-independent epitopes and therefore detects comparable Q23, Q73, and Q145 signals (Fig. 1D, left panel) ; the 2B7/MW1 combination preferentially detects the soluble monomer form of HTT with expanded polyQ (Fig. 1D , middle panel, and ref. 11) and TR-FRET using 4C9/4C9 (Fig. 1D, right  panel) . The latter assay has been used to detect soluble oligomeric and aggregated mHTT (11) . However, we largely excluded the insoluble macroaggregates through high-speed centrifugation and used this assay to measure the oligomeric form of mHTTexon1. For these experiments, the neurons are maintained under the protective conditions (see Materials and Methods) on Matrigelcoated surfaces.
When the neurons are cultured under basal conditions (see Materials and Methods) with growth factordeprived basal medium on poly-d-lysine-coated surfaces, the Q73 and Q145 stable neuronal cell lines exhibit a severe and progressive neuronal death, whereas Q23 exhibits no evidence of increased neurotoxicity ( Fig. 2A) , mimicking the neurodegeneration seen in patients with HD. The neurodegeneration is evident by multiple measures, e.g., using detection of cell number in the IncuCyte system, which captures phase-contrast images of the same fields of the cultures directly in the incubator (14) , and by Live/Dead imaging, which stains live and dead cells with green and red fluorescence, respectively. The neurodegeneration was quantified using IncuCyte software, which measures the confluence at different time points based on the phasecontrast images. Consistent with this result, similar but less dramatic phenotypes were observed recently in the hiPSC-derived Q180 neurons (7).
Rescue of the neurodegeneration phenotypes by decrease of soluble monomeric mHTT via HTT knockdown
We established an optimized siRNA transfection protocol that allows for high transfection efficiency (Ͼ90%) in these neurons ( Fig. 3C ; also see Fig. 5 ). Transfection of a previously published siRNA targeting HTTexon1 (ex1_si; ref. 13) reduces soluble, monomeric mHTTexon1 levels in Q73 neurons up to ϳ70% (Fig. 3A ) but has only a mild effect (Ͻ25%) on mHTTexon1 oligomers and essentially no effect on mHTTexon1 insoluble macroaggregates as assayed by immunostaining with EM48 (ref. 8 and Fig.  3B ). The modest reduction in oligomers and aggregates of mHTTexon1 is probably due to the slow turnover rate of aggregated mHTT in these cells. It is also noticeable that a number of Tuj1 Ϫ Q73 cells showed EM48 signals (Fig. 3B) . These are probably the signals coming from the dead cells, which accumulate over time after transfection even under protective culture conditions. Consistent with this possibility, the percentage of Tuj1
ϩ Q73 cells is much lower in younger cultures (1 d after transfection, Fig. 3D ).
Despite the fact that the mHTT oligomers and aggregates are not responsive to the effects of HTTexon1 siRNA transfection, the siRNA-mediated reduction in soluble monomeric HTT significantly rescues neurodegeneration in the HD lines in a dose-dependent manner (Fig. 2B) . As a control to mitigate any effects resulting from a change in the total siRNA concentration, nontargeting scrambled siRNA (Neg_si) was used as "filler" to hold the siRNA concentration constant. Consistent with the rescue effect, the percentage of Tuj1 Ϫ /EM48 ϩ Q73 cells is significantly lower in HTTexon1 siRNAtransfected samples than in the controls, whereas the signals of aggregates remain the same (Fig. 3B) .
Because the optimal dose of HTTexon1 siRNA (125 nM, Fig. 2B ) results in total ablation of soluble monomeric mHTT but does not reduce mHTT macroaggregates, the rescue of neurodegeneration is independent Note that the phase-contrast images taken by the IncuCyte system were from the same field, whereas the Live/Dead staining images were taken only around the starting and ending time points for different fields because the staining is toxic to the neurons after long treatment (Ͼ8 h). Right panel: confluence quantified by IncuCyte measurement of neurons based on the phase-contrast images, plotted as means and se; n ϭ 12 for Q73 and Q145, and n ϭ 8 for Q23. B) Similar to panel A, but with siRNA-transfected Q73 or Q145 neurons. Knocking down the HTTexon1 by siRNA (ex1_si) rescued neurodegeneration in a dose-dependent manner. Note that the nontargeting scrambled siRNA (Neg_si; red) and the HTT siRNA targeting a sequence outside HTTexon1 (HTT3; see of macroaggregates in these neurons. This result is consistent with previous studies showing that mHTT inclusion body formation does not predict neuronal death (15) . To evaluate the relationship between the rescue of HD neurodegeneration and the reduction of mHTTexon1 monomer and oligomer levels, the increase in neuronal survival at 48 h is plotted against the knockdown of soluble mHTTexon1 (2B7/MW1) or oligomeric mHTTexon1 (4C9/4C9) at the same time point. The rescue shows a dose-dependent relationship (logistic curve, R 2 ϭ0.997) of toxicity with knockdown of the monomeric (as detected by 2B7/MW1) but not oligomeric (as detected by 4C9/4C9) mHTTexon1 level (Fig. 2C) . In addition, the data support the conclusion that significant rescue occurs in situations in which there is no detectable knockdown of oligomeric mHTTexon1 (Fig. 2C , data points on the left side of the red line in the right panel), further supporting the possibility that soluble monomeric mHTT is the major toxic protein species that needs to be reduced for rescue.
Similarly, the time (T 40% ) needed to achieve 40% neurodegeneration (half-maximum neuronal loss in the nontargeting siRNA-transfected control samples) is used as a reference point for quantification of the delay of neurodegneration (Fig. 2D) . A clear, and robust linear relationship is observed between T 40% and knockdown of soluble monomeric (R 2 ϭ0.915; Fig. 2D , left panel) but not oligomeric (R 2 ϭ0.322; Fig. 2D , right panel) mHTT levels.
It is notable that even at the lowest concentration of HTTexon1 siRNA tested, with which soluble mHTT levels were reduced by ϳ10% and mHTT oligomers or macroaggregates were unchanged, rescue of neurodegeneration is observed (Fig. 2B) . The half-maximal rescue of toxicity was achieved at 28.9% reduction of soluble mHTT (Fig. 2C) . Therefore, HD neuronal survival appears to be very sensitive to the knockdown of soluble mHTT, making it a robust model for screening by assessing either phenotypic rescue or mHTT level modifiers.
To confirm the phenotype, we assessed rescue of neurodegeneration by an independent method, which quantifies the cell numbers by staining and counting intact nuclei. The nuclei in each well were stained with a fluorescent dye, and the IncuCyte system was used to capture fluorescent images and quantify the number of nuclei. Because of the toxicity of the nuclear dye, wells of parallel samples were used to assess survival at different time points. Similar to confluence plots, mHTT siRNA-mediated rescue of polyQdependent neurodegeneration was observed (Supplemental Fig. S2 ).
There is some evidence that subtle differences between the nuclei counting and the confluence quantification results may exist. First, nuclei are not affected by cell morphology change, such as spreading or shrinkage or neuronal processes, which can affect the confluence quantification. Second, nuclei counting cannot be performed in the same wells at different time points because of the toxicity of the dye, therefore resulting in slightly larger well-to-well and time pointto-time point variance. In general, these two independent methods gave consistent results, confirming our observations of the rescue.
To confirm that the models could potentially be used for new target discovery for HD, we tested the effect of knocking down Rhes, a gene previously reported to mediate mHTT toxicity (16) . Consistent with the literature, knockdown of Rhes significantly rescued the neurodegeneration phenotype in the mHTT-expressing hESC-derived neurons (Fig. 4) .
Up to ϳ90% loss of wtHTT is tolerated in the hESCderived neurons
Most mHTT-lowering strategies reduce the wild-type protein as well, and there are concerns in the field about the loss of wtHTT, consistent with data from animal models of loss of HTT expression. In addition, if the loss of wtHTT is not tolerated in our model, then phenotypic screening in these models might be affected by changes in wtHTT in addition to those in mHTT. We therefore tested the effect of knocking down wtHTT in the parental hESC-derived neurons using the same assays described above. Transfection of HTT siRNAs targeting full length but not exon 1 resulted in reductions of wtHTT up to ϳ90% (Fig. 5A) , with no detectable neurodegeneration over ϳ11 d (Fig.  5B, C) . This time point is ϳ10 times longer than the time window needed for detection of the neurodegeneration in mHTT stably transfected neurons ( Fig. 2A,  B) . We then tested the effect of knocking down the endogenous wtHTT in the mHTT stable line (Q73) and also did not detect any exacerbation of the neurodegeneration in the HD neurons (Fig. 5D ). This result indicates that a near complete loss of wtHTT is welltolerated in hESC-derived neurons. 
DISCUSSION
Neurodegenerative diseases are among the most difficult diseases to treat, partially because of the difficulties of obtaining a tissue-relevant assay system, such as viable human neurons. Access to relevant cell models poses significant challenges in designing screening campaigns for drug discovery. Although the recently established and characterized hiPSC-derived neuronal models address some of these challenges, there are still limitations to this system, which can be addressed by studies in other human neuronal models. Especially for HD iPSC-derived neuronal models, there is no human neuronal model to study the physiological/pathophysiological functions of different mHTT species, because mHTT fragments or aggregates were not detected in the hiPSC-derived neurons (7). The neurodegenerative phenotype seen in the iPSC is also mild, resulting in challenges for screening campaigns, e.g., because of the narrow dynamic range of the assay. Therefore, quantitative studies of the relationship between the rescue and mHTT level reduction would be challenging.
Here we present the first human stem cell-derived neuronal model exhibiting mHTT-dependent aggregates and neurodegeneration, generated from stable hESC lines expressing HTTexon1 fragments. We characterized a disease mimicking neurodegeneration in the hESCderived HD neurons expressing the mHTTexon1 transgene. The neurodegeneration is easily quantifiable, sensitive to the levels of soluble monomeric mHTT and robust for screening purposes (Fig. 2) . As supportive evidence, the phenotype could be significantly rescued by knockdown of a known regulator of mHTT toxicity, Rhes (Fig. 4) . In addition, our study is the first to show a clear quantitative relationship between rescue of neurodegeneration and knockdown of soluble monomeric mHTT (but not oligomeric or aggregated forms) in human neurons.
Based on our data, it appears that soluble mHTT is the major toxic protein species in this model. Knocking down as little as ϳ10% of the soluble monomer, without affecting the mHTT oligomers or aggregates, results in significant rescue of the neurotoxicity. In addition, in a progressive knockdown/toxicity analysis, the levels of soluble monomer correlate most consistently with the degree of protection. Because we were able to see the efficacy of the siRNA transfection when performed at the same time point as the culture condition challenge, we contend that this model provides a sensitive and simple experimental assay for potential high-throughput screening purposes.
Although strategies for monitoring wtHTT vs. mHTT are available (17) , one possible approach is to reduce total HTT level, independent of the allele. This provides the flexibility to identify targets that affect both wtHTT and mHTT and could provide additional opportunities for therapeutic intervention. Because of some phenotypes present in knockout and conditionalknockout models of HTT, it is controversial whether loss or reduction of wtHTT would have an unwanted toxic effect in neurons (18 -23) . To consider this strategy, we asked whether loss of wtHTT would have any attendant phenotypic consequences. In our tests in hESC-derived neurons, lowering wtHTT by up to ϳ90% appears to be well-tolerated within the experimental conditions and time window. Although we cannot exclude the possibility that lowering wtHTT may cause subtle phenotypes, it appears much less harmful to reduce wtHTT than to maintain the mHTT in our cellular models.
Although we need to be cautious about extending these results to treatment of patients with HD without further experiments using in vivo animal models, our hESC-derived neuronal models can be useful for initial screening and novel target identification. In addition, they provide important insights on the relative contribution of the different mHTT species (soluble vs. insoluble, monomer vs. aggregate) to the neurotoxicity. Finally, we demonstrate that almost complete ablation of wtHTT in a human neuron is well tolerated within the parameters of the assays performed. The hESC-derived neurons have several features not observed in iPSC-derived neurons: the same genetic background for HD vs. wild-type; scalability; the presence of mHTT aggregates; and a more robust and screenable neurodegeneration phenotype. These tools could be used for mechanistic and screening studies that are complementary to approaches in the hiPSC-derived neurons. 
